EDIT Editas Medicine

Editas, Beam Win Bullish Views as Cantor Launches Gene Editing Coverage

03:16

Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock

Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ:EDIT) with an Overweight rating and a price target of $15.The analyst says that following the recent pipeline reprioritization and p

02:06

Expert Ratings for Editas Medicine

Analysts have provided the following ratings for Editas Medicine (NASDAQ:EDIT) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings23930Last 30D010001M Ago01

01:01

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023

UpgradesAccording to Alembic Global, the prior rating for Woodward Inc (NASDAQ:WWD) was changed from Neutral to Overweight. Woodward earned $0.49 in the first quarter, compared to $0.56 in the year-ag

02-01 23:02

Cantor Fitzgerald Starts Editas Medicine at Overweight With $15 Price Target

08:58 AM EST, 02/01/2023 (MT Newswires) -- Editas Medicine (EDIT) has an average rating of hold and price targets ranging from $7 to $36, according to analysts polled by Capital IQ. Price: 10.15, Chan

02-01 22:01

Editas Medicine Price Target Announced at $15.00/Share by Cantor Fitzgerald

Editas Medicine Price Target Announced at $15.00/Share by Cantor Fitzgerald

02-01 19:28

Editas Medicine (NASDAQ:EDIT) Receives New Coverage From Analysts at Cantor Fitzgerald

Stock analysts at Cantor Fitzgerald initiated coverage on shares of Editas Medicine (NASDAQ:EDIT – Get Rating) in a report released on Tuesday, The Fly reports. The brokerage set an "overweight" rati

02-01 05:51

Editas Medicine Initiated With an Outperform at Cowen

02-01 05:13

Editas Medicine (EDIT) Crossed Above the 50-Day Moving Average: What That Means for Investors

01-31 00:26

Why Shares of Editas Medicine Jumped This Week

01-27 07:11